Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of organic compounds known as phenol ethers. It features an adamantane core substituted with a methylsulfonyl group and a propanamide side chain linked to a chlorofluorophenoxy moiety. The precise pharmacological action is not fully characterized; however, it has been associated with modulation of glucocorticoid metabolism—specifically influencing the reversible conversion between active and inactive glucocorticoids in humans. This activity suggests potential roles in anti-inflammatory responses and metabolic or homeostatic processes[1][2]. No approved therapeutic indication or clinical development status is currently documented.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(2-chloro-4-fluorophenoxy)-2-methyl-N-[(1R,2S,3S,5S,7S)-5-(methylsulfonyl)-2-adamantyl]propanamide.